Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

Exclusion criteria

• . Have a primary central nervous system (CNS) malignancy (eg, glioblastoma multiforme \[GBM\]);
• . Have metastasis to the CNS that is symptomatic and/or requires therapy with corticosteroids or anti-convulsant medication. However, participants who have completed treatment (radiation therapy) for CNS metastases and do not require continued treatment with corticosteroids or anti-convulsants may be enrolled in this study;
• . Have a history of Gilbert's syndrome;
• . Have a degenerative retinal disease. Retinal diseases that require a participant's exclusion include: glaucoma (with the exception of narrow angle glaucoma), hereditary retinal diseases such as retinitis pigmentosa; retinal arterial occlusive disease; and retinal disease with advanced scarring, to include age-related macular degeneration and myopic degeneration with geographic atrophy;
• . Have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of AG-270, including any unresolved nausea, vomiting, or diarrhea that is National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade \>1;
• . Have had significant active cardiac disease within 6 months prior to the start of study treatment, including any of the following:
• . New York Heart Association (NYHA) class III or IV congestive heart failure;
• . Acute myocardial infarction or angina pectoris;